Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts rate Vera Therapeutics a “Moderate Buy”: Eleven of 14 analysts recommend buying the stock, with an average 12-month price target of $81.15.
• Institutional ownership is substantial: Institutional investors and hedge funds own 99.21% of shares, while CEO Marshall Fordyce sold 46,250 shares under a pre-arranged trading plan.
• Vera shares recently opened at $32.28, below the analyst consensus target, while the company reported a quarterly loss of $1.52 per share—better than the expected $1.58 loss.

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fourteen brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $81.1538.

Several equities research analysts have issued reports on the stock. Guggenheim raised their price objective on shares of Vera Therapeutics from $56.00 to $76.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. TD Cowen increased their target price on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Needham & Company LLC set a $125.00 target price on shares of Vera Therapeutics in a report on Wednesday, July 8th. Evercore set a $91.00 price target on Vera Therapeutics in a research report on Friday, May 15th. Finally, The Goldman Sachs Group restated a "buy" rating and set a $90.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the business's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares of the company's stock, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by corporate insiders.

Institutional Trading of Vera Therapeutics

Hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Vera Therapeutics by 49.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company's stock worth $276,595,000 after purchasing an additional 1,795,537 shares during the period. Vestal Point Capital LP lifted its stake in shares of Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company's stock valued at $73,036,000 after purchasing an additional 600,000 shares during the period. Elmind Capital LP acquired a new position in Vera Therapeutics in the fourth quarter valued at approximately $24,434,000. Armistice Capital LLC boosted its stake in Vera Therapeutics by 294.1% during the third quarter. Armistice Capital LLC now owns 536,000 shares of the company's stock worth $15,576,000 after acquiring an additional 400,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Vera Therapeutics by 11.9% during the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company's stock worth $180,805,000 after purchasing an additional 379,748 shares in the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Trading Up 2.1%

Shares of NASDAQ:VERA opened at $32.28 on Wednesday. Vera Therapeutics has a 52-week low of $21.15 and a 52-week high of $56.05. The company has a market capitalization of $2.33 billion, a P/E ratio of -5.51 and a beta of 0.92. The company has a 50-day simple moving average of $36.39 and a 200 day simple moving average of $38.25. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($1.52) EPS for the quarter, topping the consensus estimate of ($1.58) by $0.06. During the same period in the prior year, the company earned ($1.20) EPS. Sell-side analysts forecast that Vera Therapeutics will post -6.46 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source